comparemela.com
Latest Breaking News On - Foundation trust david kavanagh - Page 1 : comparemela.com
Iptacopan Reduces Proteinuria, Demonstrates Benefit in C3 Glomerulopathy
In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.
Sweden
Stockholm
G-steering-committee-member-david-kavanagh
Novartis
European-renal-association-congress
Foundation-trust-david-kavanagh
Faculty-of-medical-sciences-at-newcastle-university
David-kavanagh
Steering-committee-member-david-kavanagh
Complement-therapeutics
Honorary-consultant-nephrologist
David Kavanagh, MBChB, PhD: Iptacopan Offers Hope for C3 Glomerulopathy
A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward.
Stockholm
Sweden
David-kavanagh
European-renal-association-congress
Faculty-of-medical-sciences-at-newcastle-university
Foundation-trust-david-kavanagh
Novartis
Complement-therapeutics
Honorary-consultant-nephrologist
Medical-sciences
European-renal-association
vimarsana © 2020. All Rights Reserved.